Vosoritide

Drug Profile

Vosoritide

Alternative Names: BMN-111; Modified C-natriuretic peptide; ProCNP38

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Cyclic peptides; Natriuretic agents; Natriuretic peptides; Recombinant proteins
  • Mechanism of Action C-type natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Achondroplasia

Most Recent Events

  • 27 Oct 2016 BioMarine Pharmaceutical plans an open-label extension study to a phase III trial in Achondroplasia (In children)
  • 19 Oct 2016 Efficacy and safety data from a phase II trial in Achondroplasia (In adolescents, In children) released by BioMarin Pharmaceuticals
  • 29 Apr 2016 Efficacy data from a phase II trial in Achondroplasia released by BioMarin Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top